Logo Join | About | Forum| Help | Bookmark | Login
Home Stories Groups People Marketplace | FREE Benefits
(PharmaBiz) Sopherion Therapeutics, LLC, a bio-pharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it has received Fast Track Designation from the US Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet) for first-line therapy of HER2 positive metastatic breast cancer.
 
 
Tags: Breast-cancer, breast-cancer-awareness, breast-cancer-symptoms, breast-cancer-walk
Posted By: Breast Cancer Posted 2 Years, 3 months, 6 days ago
All Votes: 1
Bookmark
Comments (0) | Who voted on this story (1) | Email this story
 

UnitedProject.org Inc. (c) 2006-2010 All content published on UnitedProject.org is provided for informational purposes only and is not meant to substitute for the advice, diagnosis or treatment provided by your physician or other healthcare professionals. If you think you are experiencing a medical problem or an emergency please contact your physician, local emergency room or call 911. Healthcare benefits and discounts are not insurance and not intended as a substitute for health insurance. Except when other source is cited, all content posted by members is licensed under Creative Commons Public Domain License.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.


Site last updated 02/11/12 - loaded in 0.0483 seconds
Website and Case Management Software powered by Paas Cloud Computing Platform